Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: May 8, 2023 (Events reported as of May 8–10, 2023)
Context: The filing reports on a Special Meeting of stockholders held on May 8, 2023, where shareholders approved the conversion of Series C and Series D Convertible Preferred Stock into Common Stock, as well as an amendment to the 2019 Long Term Incentive Plan.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The financial data provided relates strictly to capital structure and debt conversion:
- Convertible Notes Balance: £1,360,761 (principal and accrued interest) as of May 8, 2023.
- Series C Preferred Stock Issued to Note Holders: 1,149,273 shares.
- Series C Preferred Stock Outstanding (Total): 3,512,277 shares as of May 10, 2023.
- Series D Preferred Stock Outstanding: 176,462 shares as of May 10, 2023.
- Common Stock Outstanding (Pre-Conversion): 1,583,890 shares (as of record date March 10, 2023).
- Common Stock Outstanding (Post-Conversion): Approximately 2,285,849 shares.
Material Changes Versus Prior Period
The filing details significant changes to the company's capital structure effective May 9–10, 2023:
- Debt-to-Equity Conversion: Convertible notes held by Intelligent Fingerprinting Limited (IFP) note holders were converted into Series C Preferred Stock, which is subsequently being converted into Common Stock.
- Preferred Stock Conversion: All outstanding Series C and Series D Preferred Stock are being converted into Common Stock.
- Series C converts to 526,818 shares of Common Stock.
- Series D converts to 26,464 shares of Common Stock.
- Share Count Increase: The total number of Common Stock shares issued and outstanding is expected to increase from approximately 1.58 million to 2.29 million.
- Equity Plan Amendment: The number of shares authorized for issuance under the 2019 Long Term Incentive Plan increased by 50,000 shares (from 75,000 to 125,000).
Guidance, Outlook, and Risks
Management Commentary: The conversions were approved to comply with Nasdaq Listing Rule 5635. The issuances are intended to be exempt from registration under Section 4(a)(2) of the Securities Act, Rule 506 of Regulation D, and/or Rule 901.
Risks and Contingencies:
- Dilution: The conversion of preferred stock and notes into common stock significantly increases the share count, which may dilute existing shareholders.
- Regulatory Compliance: The conversions are contingent upon compliance with Nasdaq listing rules and specific terms of the Share Exchange Agreement and Securities Purchase Agreement.
Unusual Items: The filing notes that the conversion of Convertible Notes into Series C Preferred Stock is deemed effective as of May 9, 2023, while the subsequent conversion of Series C and D Preferred Stock into Common Stock is deemed effective as of May 10, 2023.
Investor Verification Checklist
- Verify the final post-conversion share count of approximately 2,285,849 shares of Common Stock.
- Confirm the elimination of the £1,360,761 Convertible Notes liability from the balance sheet.
- Review the impact of the increased share count on earnings per share (EPS) and ownership percentages.
- Check the updated 2019 Long Term Incentive Plan to confirm the new 125,000 share authorization limit.
- Ensure the company remains in compliance with Nasdaq listing requirements following the capital structure changes.